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Abstract  
Peptide amphiphiles (PAs), are novel engineered biomaterials able to self-assemble 
into supramolecular systems with applications in delivery across challenging 
biological barriers and intracellularly particularly in the field of brain diseases, 
regenerative medicine and cancer.  PAs are amino-acid block co-polymers, with a 
peptide backbone composed usually of 8-30 amino acids, a hydrophilic block formed 
by polar amino acids and an apolar block which usually entails either apolar or 
aromatic amino acids and alkyl, acyl or aryl lipidic tails and in some cases a spacer 
or a conjugated targeting moiety. Alteration in the balance between the hydrophilic 
and hydrophobic blocks result in a range of supramolecular structures that are 
usually stabilised by hydrophobic, electrostatic, β-sheet hydrogen bonds and π-π 
stacking interactions. In an aqueous environment, the final size, shape and interfacial 
curvature of the PA is a result from the complex interplay of all interactions. 
Lanreotide is the first PA to be licensed for the treatment of acromegaly and 
neuroendocrine tumours as a hydrogel administered subcutaneously, while a number 
of other PAs are undergoing preclinical development. This review discusses PAs 
architecture fundamentals that govern their self-assembly into supramolecular 
systems for applications in drug delivery. 
Keywords: peptide amphiphiles, nanofibers, self-assembly, driving forces, drug 
delivery  
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The current pressures on the pharmaceutical market, conferred by need for lower 
healthcare costs, increasing generic substitution and increased demand for efficacy 
and safety [1], have resulted into a recent surge in interest from pharmaceutical and 
biotechnology companies to peptides, proteins and antibodies. These 
biopharmaceuticals possess high potency and selectivity, which combined with their 
confinement mostly to extracellular targets, confer a favourable risk benefit ratio over 
small molecular weight APIs [2].   
Peptides have not always been the most popular candidates for drugs [3]. Peptides 
were thought to be expensive and complicated to manufacture, had exceptionally 
short half-lives resulting in chronic administration being costly and patient unfriendly 
particularly due to the need for parenteral administration as oral bioavailability 
remains for most peptides below 10% [4].  
However, peptides biodegrade into non-toxic or low toxicity metabolites while they 
possess minimal potential for drug-drug interactions and low immunogenicity 
compared to larger proteins enjoying an over 20% probability of regulatory approval, 
a rate that is double that of small molecules [3]. Compared to proteins and 
antibodies, peptides have the ability to penetrate further into tissues owing to their 
small size and are less immunogenic than recombinant proteins and antibodies [2]. 
The manufacturing costs for therapeutic peptides are lower possessing higher activity 
per unit mass, greater stability, and safe degradation products minimising the risk of 
systemic toxicity [2].  
Over the past decades, supramolecular assembly of biomacromolecules has been 
used a powerful toolbox for creating new and functional material. Peptide 
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amphiphiles (PAs) are a class of synthetic peptides modified with hydrophobic, lipid 
or lipid-like tails that have been used for bottom-up fabrication of biomaterials [5]. 
PAs combine the structural features of amphiphillic surface active molecules known 
to self-assemble into a variety of nanostructures [5] or as functional coatings on 
preformed nanostructures [6]. PAs can be exemplified by a hydrophobic tail, a linker, 
a spacer and a hydrophobic head and alterations in these basic structural segments 
can control the resulting morphology (micelles, vesicles, nanotubes, nanofibers, 
nanosheets), surface chemistry and even function.  Peptide amphiphiles assemble 
into a variety of structures mediated by electrostatic interactions between charged 
amino acids, hydrogen binding, π-π stacking interactions and hydrophobic 
associations [7, 8].  Hence, many PAs are currently explored as nanomaterials for 
various applications including regenerative medicine [9], gene [10] and drug delivery 
[11]. This review will focus on the parameters affecting supramolecular engineering 
of peptide amphiphiles as their chemical structure and forces driving the self-
assembly and the applications of peptide amphiphiles in the field of drug delivery.  
2. Amino acids: The Molecular Building Blocks 
Whereas synthetic polymers are usually formed by the polymerization of a one to 
three building blocks, proteins are composed of 20 different amino acids [7]. This 
high number of building blocks and the peptide sequence can provide a wide 
diversity of molecular characteristics. The amino acid building blocks are categorised 
in non-polar, polar and others [8, 12]. Non-polar amino acids are divided into two 
groups: aliphatic [alanine (A), leucine (L), valine (V), isoleucine (I) and methionine 
(M)] and aromatic [tyrosine (Y), phenylalanine (F) and tryptophan (W)] which may 
contribute to hydrophobic clustering. The aliphatic residues favour hydrophobic 
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interactions, while the aromatic amino acids can also be involved in π-π stacking that 
have been increasingly recognized as relevant in the peptide self-assembly [8]. The 
polar, uncharged amino acids, serine (S), threonine (T), asparagine (N), glutamine 
(Q), are involved in hydrogen bonding interactions through -OH (S, T) or -CONH (N, 
Q) groups [8]. However, there are five charged amino acids (positive charged: 
histidine (H, pKa 6.5), lysine (K, pKa 10), arginine (R, pKa 12), and negatively 
charged: aspartic acid (D, pKa 4.4), glutamic acid (E, pKa 4.4)) able to establish 
electrostatic interactions that aid in forming assemblies (exploiting oppositely charged 
groups) or in preventing assembly (exploiting electrostatic repulsion) [8]. From the 
remaining building, glycine and proline are strand directing residues. Glycine 
introduces a high level of flexibility comparing to other amino acids, mainly due to the 
lack of steric hindrance induced by the side chain [13, 14]. Proline, on the other hand, 
confers a conformational rigidity to the peptide due to the locked conformation 
caused by the side chain being covalently linked to the amino terminus [8] and is 
commonly found in turns or at the beginning of an α-helix and in the edge strands of 
a β-sheet. Cysteine, due to the presence of the reactive thiol group in its side chain 
can be chemically modified (e.g. via maleimides) or via disulphide bonds 
intermolecularly. Furthermore, tyrosine, serine and threonine, hydroxyl group-
containing amino acids, are also used for chemical or enzymatic modification [8, 11, 
15]. Finally, the peptide backbone itself can confer stability via hydrogen bonds.  
Even peptides as short as dipeptides can orderly arrange into a variety of different 
structures and particularly, dipeptides containing at least one phenylalanine. 
Diphenylalanine has been shown to produce rigid nanotubes with a Young’s elastic 
modulus of 19GPa via π-stacking [16, 17]. Fmoc-diphenylalalanine peptides forms 
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hollow peptide tubes (50 - 1000nm  in diameter) able to form hydrogels 
spontaneously [18].  
3.   Peptide amphiphile blocks   
With amino-acid block co-polymers, the peptide backbone composed of 8-30 amino 
acid long with the polar amino acids form the hydrophilic block and the apolar amino 
acids and grafted alkyl, acyl or aryl lipidic tails forming the hydrophobic block [5, 8, 
12, 19-21] (Figure 1A). In some cases, it is possible to also be composed of a linker 
or a spacer in between the two blocks if needed such as polyethylene glycol (2KDa) 
[22] or glycine spacers [23]. The hydrophobic blocks are tunable containing, usually, 
3-9 apolar amino acids or 12-16 carbons in the acyl or alkyl chain [12]. As for all 
amphiphiles the critical  aggregation concentration is critical to their stability [24] with 
this value ranging between nanomolar [15, 22, 25] to micromolar concentrations [26, 
27] depending on the nature of the hydrophobic block.  This is an important 
consideration if in vivo drug delivery applications where dilution with biological fluids 
is inevitable. Additionally, the aqueous solubility of the PA and, consequently its 
aggregation in water, is also greatly dependent on the hydrophobic block with larger 
tail lengths resulting in enhancement in aggregation propensity [5]. A strong ability to 
form intermolecular hydrogen bonds between the hydrophobic amino acid results 
commonly in β-sheets that are critical for the stability and morphology of the 
assemblies [5, 28]. On the other hand, the hydrophilic block consists primarily of 
charged amino acids and can confer some pH-responsiveness to the assemblies [5, 
28], which can be used to control the morphology of the assembly [29-32]. For 
example, a coiled-coil a-helix with leucine at position d and glutamic acid residues at 
positions e of an abcdef heptad leucine zipper  (SGDLENEVAQLEREVRSLEDEAAE 
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LEQKVSRLKNEIEDLEAE) forms homodimeric coiled-coils which are destabilised in 
basic solutions [29]. Incorporating glutamic acid and lysine pairs at the e and g 
positions to stabilise the coiled-coil of leucine zippers 
(KIAALKQKIASLKQEIDALEYENDALEQ and KIRALKAKNAHLKQEIAALEQEIAALE 
Q) resulted in nanosized fibres that unwind into random coils in response to an 
increase in ionic strength as these charges were screened, destabilising the helix–
helix interaction [30-32]. By designing an amino acid sequence that resembled both 
that of a leucine-zipper coiled-coil and that of a b-hairpin (Ac-
YGCVAALETKIAALETKKAALETIAALC-NH2), a system was created able to change 
the conformation from a-helix to b-hairpin when heated, while also consequently 
forming a gel [30-32]. 
 
Peptide amphiphile structure can be modified by incorporation of peptide sequences 
known to be substrates for proteases, kinases or phosphatases to elicit enzyme 
responsiveness of the final assembly [33, 34]. Similarly, introducing signalling 
epitopes such as the RGDS sequence [19, 35-37] or IKVAV [38, 39] which can 
confer certain properties such as cell adhesion or neural adhesion, migration and 
neurite growth respectively.  
 
Thus, by carefully engineering the structure of peptide amphiphiles, it is possible to 
tailor the morphology, stability, and function of the resulting supramolecular 
assemblies.  
4. Forces driving the self-assembly of PAs 
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PAs self-assembly is driven by hydrophobic interactions, hydrogen bonding, π-π 
stacking and electrostatic interactions (Figure 1A) adding to the diversity of 
engineered assemblies.   
4.1 Hydrophobic Interactions 
Hydrophobic interactions occurring in the non-polar amino acid region of the peptide 
associated with a lipidic tail result in the formation of a hydrophobic core usually 
present within nanofibers in water [24]. These attractive forces are a direct result of 
the interfacial tension of the lipidic tail-water interface [40-46]. Hydrophobic 
interactions are less geometrically constrained compared to electrostatic interactions 
[28] and the tail length is an important engineering parameter for stable peptide 
amphiphiles. Gore et al. using a model collagen peptide headgroup investigated the 
effect of the number of tails and temperature on the self-assembly of collagen 
mimetic PAs [40]. Amphiphiles containing a single or double tail of C12 to C14 
formed spherical micelles but PAs with longer tails aggregated into disc-like micelles 
that stacked up to form a strand-like structure. Only peptides with longer tails, C18 
and C20, were affected, in terms of aggregate secondary structure from helical which 
is restored by the increase of temperature. PAs with hydrophobic alkyl chains with 
different lengths (C9, C11, C13 and C15) and a hydrophilic headgroup of VRGDV 
(Val-Arg-Gly-Asp-Val) formed nanofibers at a neutral pH of 7 [42]. However, at 
increased pH, the PAs with shorter tails, C9 and C11, assembled into micelles, 
instead of fibers, with a width of ~30 nm [42]. Thus, increasing the length of the 
hydrophobic tail results in tightly packed due to stronger hydrophobic interactions 
driving the self-assembly process providing stability to pH changes.  Altering the 
combination of non-polar amino acid residues within the PA sequence can also 
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confer steric topologies that can affect the self-assembly process. Substituting the 
Phe (F) residues with non-polar residues of different size (G, A, V, L, and I) in model 
peptides (FEFEFKFK)2 alters the co-operative binding between different hydrophobic 
areas of the peptide chains in formation of b-sheets [41]. Finally, manipulation of the 
hydrophobic region of the Pas by introduction of phospholipids, namely 1-palmitoyl-2-
hydroxy-sn-glycero-3-phosphocholine, can modulate the mechanical properties of the 
assemblies and elicit hydrogels when the lipid constitutes the 20% of the total 
molecular weight formed by non-covalent hydrophobic interactions [44, 47].  
Table 1: Driving forces involved in self-assembly. Modified from [48] 
Type of interaction Strength (kJ/mol) Properties 
Electrostatic 50–300 Short ranged, Non-selective 
Coordination binding 50–200 Short ranged, Directional 
Hydrogen bonding 5–120 Long ranged, Selective, Directional 
π–π Stacking 0–50 Short ranged, Directional 
Solvophobic Depends on solvent type Short ranged, Little directional constraint 
van der Waals < 5 Short ranged, Non-directional, Non-selective 
Covalent 350 Short ranged, Irreversible 
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Figure 1 A: Different classes of amino acids and types of interactions they are 
involved in, B: Schematic representation of PAs self-assembly driving forces 
(Modified from [28, 49]).   
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4.2 Hydrogen bonding  
Peptide nanofibres are normally formed form β-sheet forming peptide chains linked to 
a terminal alkyl group forming a central hydrophobic core [7, 43, 50-55]. Hartgerink 
and coworkers., using a series of Kn(QL)6Kn peptides, investigated the forces 
involved in the peptides self-assembly into nanofibers [51]. The hydrophobic packing 
of the non-polar leucine is driving the assembly, but does not control the morphology 
of the self-assembled peptides, which is in turn stabilised only via formation of β-
sheets and hydrogen bonding directing the anisotropy of the structure [51].  Using a 
surfactant like peptide with a glycine spacer separating the hydrophobic from the 
polar charged region of the amphiphile (C16G7ERGDS),  Paramonov et al. illustrated 
that methylations of the four glycines closest to the core of the nanofiber, in the 
proximity of the hydrophobic alkyl tail eliminates the ability of a PA to form elongated, 
cylindrical nanostructures, and thus its ability to gel [50]. However, methylation of the 
three glycine residues closer to the hydrophilic region resulted in the abolishment of 
the β-sheet and formation of polyproline type II structures. The polyproline type II 
(PPII) conformation forms extended form turns counterclockwise (left-handed) and 
contrary to the a-helix and β-sheet conformation, it is not cooperative and it is 
typically found in equilibrium with dihedral angles of the extended β-sheet [56]. Thus, 
PPII conformation are less ordered as they are not stabilised by hydrogen bonds and 
the PPII dihedral angles of one amino acid is energetically favoured by the equal 
conformation of the neighbouring amino acids [57]. However, in peptide self-
assemblies, the PPII conformation remains largely unexplored.  
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 Dong et al. [51] illustrated the need for a balance between the hydrophilic and 
hydrophobic attractive forces using a model ABA tri-block peptide (Kn(QL)mKn). 
When m/n ≥ 3, soluble peptide nanofibers  with a diameter of 6 ± 1 nm diameter and 
length 120 ± 30 nm were fabricated from a decapeptide (m+2n=10) stabilised by β-
sheets. Similarly, the cooperative effect of these driving forces were investigated 
using shorter PAs: I(3-5)K, L(3-5)K and LI2K [43]. Leucine residues had a weaker 
tendency in promoting β-sheet structures compared to isoleucine residues with the 
hydrophobic interactions being predominant compared to axial hydrogen bonding in 
isoleucine PAs. At least 4 leucine residues were necessary for β-sheet stabilised 
nanofibers to form, while increasing the number of isoleucine residues had no effect 
in the self-assembly of the PAs but only to their diameter and length [43].  
 
4.3 π-π Interactions 
The critical involvement of π-π interactions was illustrated by diphenylalanine 
dipeptides forming nanotubes via π-stacking and hydrogen bonding [16-18, 58], 
which is the core recognition element of the Alzheimer’s α-amyloid polypeptide. Other 
researchers have illustrated the significance of π-π stacking by studying N-(fluorenyl-
methoxycarbonyl) (Fmoc) amino acids interactions and illustrated that π-π 
interactions between the fluorenyl groups provided part of the required linkages for 
the gelation [59].  Studies using Fmoc-diphenylalanine illustrated that anti-parallel β-
sheets can form tubular structures able to gel formed by the interlocking through π-π 
interactions of four twisted β-sheets [60]. The contribution of aromatic amino acids as 
phenylalanine (F), tyrosine (Y) and tryptophan (W) in π-π interactions was assessed 
using ABA triblock PAs (K2(QF)6K2, K2(QY)6K2 and K2(QW)6K2 peptides)  [61]. The 
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type of aromatic amino acid selected affect the length and stability of resulting 
nanofibers with phenylalanine producing anti-parallel β-sheets, long fibers and stable 
hydrogels, while tyrosine and tryptophan yielded parallel β-sheets, short fibers and 
hydrogels with poor properties. Despite the differences in side chain bulkiness, the 
intra-tape spacing between the peptides remained close to 0.48 nm for all 
multidomain peptides in both parallel and anti-parallel orientation, which allows 
optimal hydrogen bonding in both cases. The balance of intermolecular aromatic-
aromatic interactions and hydrogen bonds has been shown to be critical in 
preparation of biocompatible short PAs (pentapeptides) containing tyrosine and 
phenylalanine residues (at least 2 aromatic amino acids per peptide sequence) that 
can act as hydrogelators in a concentration of 0.5-2.8% w/v [62]. Interestingly, the 
introduction of a conformational constraint by disulfide-bond-mediated peptide 
cyclization was able to disrupt aromatic-aromatic interactions of a short PAs (Ac-
C(FKFE)2CG) and enable the creation of a responsive amphiphile able to gel in 
reductive environments by favouring the adoption of β-sheet conformation [63].  
4.4 Electrostatic Interactions 
Electrostatic interactions between the charged amino acids of the hydrophilic head, 
as well as the hydrophobic tail interactions, are dominant non-selective driving forces 
of the PAs self-assembly (Table 1). Israelachvili has described that balance between 
attractive (hydrophobic) and repulsive (electrostatic) forces are critical in determining 
the geometry of amphiphiles with minimum free energy [24]. The critical packing 
parameter (CPP) characterised by the molecular area of the hydrophilic head, a, the 
molecular volume of the hydrophobic tail, v, and the molecular length of the 
hydrophobic tail, l, can be used to predict the morphology of the overall assembly:  
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𝐶𝑃𝑃 =
v
𝑎ol
          (Equation 1) [24].  For 
fibrils to result, a CPP value of  between 1/3 to ½ is necessary [7].  
 
 
Figure 2: Molecular structure of amphiphiles, preferred aggregate structures, and the 
related aggregate curvature. Reproduced with permission from:  [64] 
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Modifications of the hydrophilic region in terms of size and charge can gravely affect 
the self-assembly with increase in size reducing proportionally the CPP [65, 66], 
which can result in a spherical morphology, if this reduction is adequate [51]. 
Enhancing the amphipathicity of PAs can result in more stable assemblies. De-
amination of Ac-A6K-CONH2 exposed the carboxyl group and yielded a negative 
charge to the hydrophilic region that resulted to a PA with a lower CAC and 
enhanced stability [65]. Alternatively, amphipathic X6Kn peptides (where X is a 
hydrophobic amino acid i.e. A, V, or L)  with identical hydrophobic regions, but with 
an increased number of hydrophilic amino acids possess an increased CAC (from 
micromolar to millimolar range) and formed vesicles or irregular aggregates 
compared to nanotubes [66].  
 
Beyond experimental studies of the self-assembly of PAs, a number of theoretical 
calculations have been reported to predict the self-assembly of PAs [67-73]. Most 
recently, the Schatz group investigated the assembly of the SLSLAAAEIKVAV 
peptide using steered molecular dynamics simulations [71] and targeted molecular 
dynamics simulations [72]. Obtained data indicated that the driving forces for self-
assembly are enthalpic with electrostatic and, mainly, van der Waals interactions 
playing an important role in the stabilization of the nanofibers [71]. The total 
electrostatic interactions contributed towards the 86% of the total driving force of 
which 54% were solvent electrostatic interactions while van der Waals forces 
contributed to 12% of the total driving force [72]. Overall the mechanistic picture for 
PA self-assembly is that the PAs transfer from free state to bound state occurs in two 
stages based on these predictions: i) PAs approach each other while aggregation, 
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desolvation, and head−tail conformational reorganization occurs (this stage can be 
viewed as being dominated by PA movement toward the center of the micelle, while 
solvent moves away); ii) PAs organize together to make a conformational disorder-to-
order transition, including forming more secondary structures and tail−head 
core−shell alignment associated with a rapidly decreasing potential of mean force 
(PMF) [72].. In the first stage, the PMF decreases smoothly (and slowly) as  the 
solvent−solvent and PA−solvent interaction energies show additional structure as a 
function of Rg (radius of gyration) in which PA−solvent and solvent−solvent 
interactions change more rapidly at long range ( >45 Å) than at shorter range. This 
long- range variation arises from desolvation of the PA head groups as the PAs come 
together [72].  
 
Beside hydrophobic, hydrogen bonding, π-stacking and electrostatic interactions, 
Stendahl et al. described the effect of the concentration, electronic structure and 
hydration of the counterions on the self-assembly of a C16A4G3S(P)KGE-COOH PA 
[49]. Atomic force and transmission electron microscopy studies illustrated formation 
of PA gels when metal particularly divalent chelators were added (i.e. Ca+2) [49].  
Higher valence ions, f, p and d-block elements, revealed the formation of elastic gels 
while lower valence ions, s-block elements, gels were classified as viscous liquids 
[49]. 
 
5. Applications of PAs in Drug Delivery 
The ability of the PAs molecules to organize into well-defined nanostructures, 
micelles, vesicles, nanospheres, nanofibers and nanotubes, is clearly relevant for 
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drug delivery considering the potential of the PAs in permeating biological barriers as 
well as safe degradation products (Table 1).  
5.1 Clinically translated supramolecular PA assemblies 
The only licensed PA supramolecular assembly was approved by the Food and Drug 
Administration (FDA) based on lanreotide, a somatostatin analog. Somatostatin is a 
hormone regulating gastrointestinal tract modulation and proliferation of normal and 
tumour cells. Lanreotide (Figure 3) is licensed for the treatment of acromegaly and 
for the treatment of neuroendocrine tumours and is currently available as Somatuline 
LA ®  that requires intramuscular administration once every 10-14 days or as a 
subcutaneous monthly implant, Somatuline Autogel© [74]. Lanreotide has been 
shown to spontaneously self-assemble into monodisperse nanotubes [75]. 
Lanreotide (cyclic octapeptide, H-D-2-NAL-CYS-TYR-D-TRP-LYS-VAL-CYS-THR-
NH2) is able to self-assemble in aqueous environments at concentration of 3-18% 
w/w by forming hollow nanotubes with a 24.4 nm diameter and lengths up to 
hundreds of micrometers [75-80]. Each nanotube wall consists of 26 helicoidal 
filaments that are formed by peptides self-assembled into anti-parallel β-sheets 
through an alternating pattern of the aliphatic and aromatic amino acids [75]. The 
effect of the peptide concentration, 2 to 70% (w/w), and temperature, 15 to 70 ºC, 
was studied by Valéry et al. [76]. The results revealed the hexagonal packing of 
nanotubes, and high degree of monodispersity in the tube diameter (244 Å) and wall 
thickness (~18 Å) [75]. Using Raman and fluorescence spectroscopy, it was shown 
that the molecular and supramolecular packing of lanreotide is stabilized by 1) 
naphthalene side chains involved in specific molecular interactions/orientations, 2) 
tyrosines that stabilize the filaments and the double-walled layer of filaments and 3) 
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W-W aromatic packing, in which the tryptophans residues are oriented inward or 
outward from the nanotube layers towards the water modulating the tube curvature 
[77]. The modification of the conformation by opening the cycle, replacing the lysine 
or the aromatic amino acids with alanine, with the latter abolishing nanotube 
formation, illustrating the importance of the aromatic residues in the lanreotide self-
assembly [78].  
 
Figure 3: A: Lanreotide chemical structure, B: Somatuline Autogel ® final dosage 
form and administration details, C: Schematic view of the different hierarchical levels 
in the self-assembly of the lanreotide-acetate nanotubes in water; a) Lanreotide 
molecule in the hairpin planar conformation is stabilised by the disulphide bridge, the 
turn and the intramolecular hydrogen bonds, b) The structure of a filament with two 
different β-sheet fibers superimposed with their C2 2-fold axes (black circles) meeting 
together , c) Self-assembly of 26-sheets fibers to form a nanotube, d) Liquid 
crystalline hexagonal columnar phase formed by the nanotubes.  Modified with 
permission from: [75] 
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Table 2 Summary of studies of PAs developed for drug delivery applications. 
Phase PA Drug Nanostructure Route Application Outcome Ref. 
Clinical 
Lanreotide 
NH2-(D)Naph-CY(D)WKVCT-
CONH2 
- Nanotubes 
IM 
SC 
Acromegaly and TSH-
secreting pituitary 
adenomas 
Significant reduction in the tumour 
size. Reduction or normalisation 
of circulating GH (57% of 
patients) and IGF-1 levels (67% 
of patients) (meta-analysis of 44 
studies) 
[74, 
75, 
81] 
Preclinical 
In vivo 
Leucine-Enkephalin 
NH2-Y(-O-palmitoyl)GGFL-OH 
Leucine-
Enkephalin 
Quaternary 
ammonium 
palmitoyl chitosan 
coated nanofibers 
IV 
Oral 
Pain 
Antinociception lasting 2 – 8 h 
after oral administration. 
Increased brain uptake after oral 
(67%) and IV administration 
(50%).  
[11, 
15] 
NH2-Y(-O-palmitoyl)GGFLR-OH Dalargin 
Quaternary 
ammonium 
palmitoyl chitosan 
coated nanofibers 
IV Pain 
Significant antinociception 
between 1-3 hrs post IV dosing 
[25] 
RAD16-II 
AcN-(RARADADA)2-CNH2 
IGF-1 Nanofibers 
Local 
injection 
Myocardial infarction 
Specific and prolonged delivery of 
IGF-1 increasing cardiomyocyte 
growth in vitro and in vivo  
[82] 
Palmitoyl-G3A4IKVAV - Nanofibers 
Local 
injection 
Spinal cord injury 
Reduced astrogliosis and cell 
death and regeneration of motor 
and sensory neurons 
[39] 
Palmitoyl-V2A2E2-NH2 SHH Nanofibers 
Local 
injection 
Cavernous nerve injury 
Regeneration of the nerve, 
suppression of penile apoptosis 
and 58% of improvement of 
erectile function 
[83] 
Palmitoyl-V2A2E2K 
Dexametha-
sone 
Nanofibers SC inflammation 
Significant reduction in 
inflammation with a low number of 
infiltrating inflammatory cells 
[84] 
Palmitoyl-A4G3E3 Camptothe-cin Nanofibers IV Cancer 
2.5-fold decrease of breast 
cancer xenograft growth  
[85] 
Palmitoyl-(K)-
V3E3SGGGYPVHPST-NH2 
BMP-2 Nanofibers 
Local 
implantation 
Spinal arthrodesis 
10-fold reduction in dose 
necessary to achieve 100% 
fusion rate and 42% fusion rate 
without exogenous BMP-2 
[86] 
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In vitro 
Chol/Palmitoyl-A4G3KRGDS 
Chol/Palmitoyl-
A4G2EGRGDS 
Pyrene 
(as a model 
drug) 
Nanofibers - 
Delivery of 
hydrophobic drugs to 
tumours 
Efficient encapsulation of 
pyrene in the nanofiber 
hydrophobic core 
[87] 
Dipalmitoyl - 
(LRKLRKRLLR)2 
- Micelles - 
Intracellular delivery 
of hydrophobic drugs 
Efficient internalization of 
micelles into mouse brain 
capillary endothelial cells 
[88] 
Dioctadecyl-L5CCK8 
Pyrene  
Doxorubicin 
Micelles - 
Delivery of 
hydrophobic drugs 
Fluorescence experiments 
indicated the entrapment of 
pyrene/doxorubicin within the 
PAs 
[89] 
Ac-AAVVLLLWE2/7-COOH 
Calcein 
(as a model) 
Vesicles - 
Delivery of 
hydrophilic drugs 
Formation of pH-sensitive 
vesicles loaded with a water 
soluble molecule 
[90] 
Palmitoyl-
GTAGLIGQRGDS-COOH 
Cisplatin Nanofibers - 
Ovarian, testicular 
and bladder cancer, 
lymphoma and 
glioma 
Loading efficiencies of 98.7%. 
Drug release triggered by the 
cleavage of MMP-2-sensitive 
sequence in the peptide  
[91] 
(AF)6H5K15 
Doxorubicin 
and p53 
gene 
Micelles - Hepatocarcinoma 
Drug loading of 22%. 
Simultaneous intracellular 
delivery of the drug and the 
gene into HepG2 cells  
[92] 
Palmitoyl-A4G3LRK2LGKA 
VEGF and 
FGF-2 
Nanofibers - Type 1 Diabetes 
Improvement of transplanted 
pancreatic islets survival and 
4.5-fold increase of cell 
sprouting. Increased glucose 
secretion 
[93] 
Palmitoyl-A4G3(KLAKLAK)2 - Nanofibers - Cancer 
Death of breast cancer cells 
induced by caspase-
independent and Bax/Bak-
independent mechanisms 
associated with membrane 
lysis 
[94] 
Palmitoyl-(ADA)2-RGD 
Octadecyl-(ADA)2-RGD 
Paclitaxel Micelles - 
Ovarian, breast, lung 
cancer, acute 
leukemia and others.  
Palmitoyl-(ADA)2-RGD 
micelles exhibited lowest 
CMC, 9±1.73μM, and cellular 
uptake by A2058 melanoma 
cells 
[95] 
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H(L)K3((L)W(D)L)3(L)W-NH2 
Ac((L)Ac)3((L)W(D)L)3(L)W-
NH2 
BODIPY630 
Alexa488 
Doxorubicin 
Paclitaxel 
siRNA, DNA 
Nanospheres - 
Vehicle for delivery of 
diverse drugs and 
genes 
Cell death of THP-1 
monocytes caused by the 
doxorubicin or paclitaxel.  
[96] 
 
Key: BMP-2 (bone morphogenetic protein-2), Chol (cholesterol), CMC (critical micelle concentration), FGF-2 (fibroblast growth factor-2), IGF-1 (insulin-
like growth factor-1), IM (intramuscular), IV (intravenous), MMP-2 (matrix metalloproteinase-2), NPs (nanoparticles), PEG (poly(ethylene glycol), SC 
(subcutaneous), SHH (sonic hedgehog), TSH (thyroid-stimulating hormone), VEGF (vascular endothelial growth factor); FGF-2 (fibroblast growth factor-
2). 
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5.2 Preclinical studies 
Only peptide nanofibers are at the moment undergoing preclinical research 
mainly in the area of delivery across the blood-brain barrier, the oral mucosa, 
regenerative medicine, inflammation and cancer (Table 2) with majority of PAs 
containing a palmitoyl single tail. Peptide nanofibers have shown promise in 
delivering peptides across challenging barriers such as the oral mucosa and the 
blood-brain barrier [2]. Due to their amphipathic structure they are able to 
permeate better across biological barriers, while self-assembled peptide show 
superior enzymatic stability to digestive enzymes as well as plasma, brain and 
liver enzymes [15]. Pharmacokinetic studies of two PAs of leucine-encephalin 
(an endogenous opioid neuropeptide) synthetic analogues [NH2-Y(-O-palmitoyl) 
GGFL-OH (TPLENK) and NH2-Y(-O-palmitoyl)GGFLR-OH) TP-Dalargin] 
illustrated that nanofibers permeate across the blood-brain barrier in significant 
amounts and able to achieve central antinociception after intravenous [11, 25] 
and oral administration [15], and there are they only studies reporting 
pharmacokinetic parameters for PAs self-assemblies. Nanofibers consisted of 
central hydrophobic core surrounded by a β-sheet of peptides.  As the alkyl 
chains associate, this β-sheet formation confounds the self-assembly and 
prevents the assembling molecules from achieving a marked radius of curvature 
and spherical shape, instead giving rise to a hydrophobic cylindrical assembly 
surrounded by a β-sheet, with the cylindrical assembly primarily driven by the β-
sheet formation. The presence of charges amino acid such as the positively 
charged arginine residue [5] in TP-Dalargin is not critical for self-assembly as 
TPLENK is able to self-assemble due to aromatic stacking and solvophobic and 
hydrophobic interactions [7, 11]. Quaternary ammonium glycol chitosan 
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polymers were used to coat the resulting nanofibers which resulted in reduction 
of protein binding and liver uptake of nanofibers and aided in enhancing the 
brain bioavailability of the nanofibers after intravenous administration [11] and 
enabled the oral uptake of peptide nanofibers across the oral mucosa [15].   
 
Figure 4: A: Acylated Leucine Enkephalin (TPLENK) PA structure and 
schematic view of the different regions of the PAs and forces driving its self-
assembly in nanofibers in water, B and C: Transmission electron microscopy 
images of TPLENK nanofibers (4% w/v in 2.25% glycerol) and quaternary 
ammonium glycol chitosan (GCPQ 10kDa) polymer overcoated TPLENK 
nanofibers (4% w/v in 0.9% sodium chloride, PA : polymer ratio: 1:5 w/w), D: 
Tail-flick bioassay % antinociception (mean ± SEM, n = 16) recorded for orally 
dosed mice with water (▲), leucine-enkephalin (70 mg kg−1, ), TPLENK (100 
mg kg−1) − GCPQ (14kDa, 500 mg kg−1) (●). Modified from [11].  
 
 
Peptide amphiphiles are under intense research in the field of regenerative 
medicine and tissue regeneration [39, 82, 83]. An example of this is a “biotin 
sandwich” approach was described for the controlled delivery of insulin-like 
growth factor (IGF-1) to local myocardial infarction environments for cardiac 
repair [82]. Biotinylated IGF-1 was complexed with tetravalent streptavidin and 
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then bound to biotinylated self-assembling peptides RAD16 II (AcN-
(RARADADA)2-CNH2) peptides. These fused growth factor with self-assembling 
peptides resulted in a five-fold increase of the IGF-1 binding comparing to the 
non-biotinylated peptides [82], while the peptides with tethered IGF-1 promoted 
the long-term activation of survival pathways and increase the expression of the 
cardiac maturation markers. Adult sprague Dawley rats suffering from a 
myocardial infarction, were immediately exposed to cardiomyocytes alone of 
embedded within the self-assembling peptides (80µL) into the infarct zone via a 
30-gauze needle. After 21 days, the tethered IGF-1 promoted a significant 
reduction of the implanted myocytes apoptosis compared to the RAD16II alone 
or untethered IGF-1 [82]. Over the last years, the Stupp group has reported on 
the potential of PAs for the regeneration of spinal cord and cavernous nervous 
injuries [39, 83, 97]. PA (palmitoyl-G3A4IKVAV) incorporating the neuroactive 
epitope from laminin (IKVAV) promoted the outgrowth of processes from in vitro 
cultured neurons and suppress the astrocytic differentiation of neural progenitor 
cells [38]. Local injection of palmitoyl-G3A4IKVAV in a mouse spinal cord injury 
model resulted in 1.5-fold decrease of glial fibrillary acid protein (GFAP) 
immunofluorescence, cell death reduction and increase of the oligodendroglia at 
the lesion site [39]. The IKVAV PA promoted also the regeneration of the 
descending motor and ascending sensory neurons [39].  
 
PAs have also shown potential in peripheral nervous system regeneration 
especially of the cavernous nerve [83]. Peripheral nerve injury of the cavernous 
nerve (CN) is a significant concern to diabetic, aging, metabolic syndrome and 
prostate cancer patients who develop erectile dysfunction (ED) as a result of 
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denervation of the penis [83]. The sonic hedgehog (SHH) protein has been 
shown to have beneficial effects in cavernous nerve injury and regeneration [98, 
99] and therefore, in preventing penile apoptosis and erectile dysfunction. Thus, 
delivery of SHH entrapped by palmitoyl-V2A2E2-NH2 nanofibers to the cavernous 
nerve after local injection suppressed the penile apoptosis and caused a 58% 
improvement in erectile functional in less than half of the time reported in the 
literature [83].  
 
Modular PAs assembled in nanofibers (palmitoyl-V2A2E2K) have also shown 
beneficial effects in immunosuppression to improve cell or tissue transplantation 
[84]. Conjugation of an anti-inflammatory drug, dexamethasone via a 
hydrolytically labile hydrazine bond to peptide nanofibers enabled a faster 
release of the steroid at weekly acidic pH (pH 5-6) compared to physiological 
(pH 7.4) [100]. Cumulative release studies of dexamethasone-conjugated 
nanofibers displayed minimal burst release and zero-order release kinetics with 
sustained release over 32-day study. At the end of the study, only 40% of the 
total amount of drug was released from the nanofibers gel. Free 
dexamethasone mixed with the peptide revealed a greater burst release at the 
initial time points and then, a faster release profile with all the drug released in 
32 days [84]. Histological studies in mice illustrated a marked reduction in the 
number of infiltrating inflammatory cells when cell-surrogate polystyrene 
microparticles impanted in mice were delivered within Dex-PA nanofiber gels, 
and very little inflammation was observed at either 3 days or 21 days post-
implantation [84].  
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PAs nanofibers also finally have illustrated potential in the treatment of breast 
cancer by exploiting EPR effect. High encapsulation of camptothecin (a 
naturally occurring quinoline alkaloid) into palmitoyl-A4G3E3 peptide nanofibers 
was achieved (loading efficiencies of 72%) and enabled a 50-fold enhancement 
in camptothecin aqueous solubility [85]. Small-angle X-ray scattering results 
suggested a slight increase in diameter of the nanofiber to accommodate the 
hydrophobic cargo and treatment with camptothecin loaded nanofibers resulted 
in a 2.5 fold decrease in  breast cancer xenograft murine model [85].   
PA nanofibers (Palmitoyl-(K)-V3E3SGGGYPVHPST-NH2) with binding affinity 
for the bone promoting growth factor BMP-2 have been reported to create a gel 
scaffold for osteogenesis [86]. The efficacy of the bioactive PA system to 
promote BMP-2-induced osteogenesis in vivo was investigated in a rat 
posterolateral lumbar intertransverse spinal fusion model. PA nanofiber gels 
displaying BMP-2-binding segments exhibit superior spinal fusion rates relative 
to controls, effectively decreasing the required therapeutic dose of BMP-2 by 
10-fold [86]. A 42% fusion rate was also observed for gels containing the 
bioactive nanofibers without the use of exogenous BMP-2, suggesting the ability 
of the PA nanofibers to recruit endogenous growth factors [86]. 
5.3 In vitro Studies 
A greater variety of PAs are explored in in vitro studies for cancer therapy [91, 
92, 94, 95], type 1 diabetes [93] and as models for the delivery of hydrophobic 
[87-89] and hydrophilic drugs [90]. A modular PA created between the 
attachment of a palmitoyl tail to a cell adhesive matrix metalloproteinase-2 
(MMP-2) sensitive peptide (GTAGLIGQRGDS) has shown potential in vitro for 
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the targeted treatment of testicular, ovarian and bladder cancer as well as 
lymphoma and glioma [47, 91, 101] (types of cancers known to overexpress 
high levels of MMP-2 which playing a critical role in tumour progression, 
angiogenesis and metastasis [1, 102]. RGDS peptide is a tetrapeptide found on 
fibronectin, fibrinogen α, and von Willebrand factor able to interact with α5β1 and 
αvβ3 integrins. Release studies showed that MMP-2-triggered cisplatin release 
from the nanofibers occurred in a spatially and temporally controlled drug 
release via RGDS-mediated cellular interaction and MMP-2 specific 
biodegradation, which suggests a possible use of palmitoyl-GTAGLIGQRGDS 
peptides to control the in vivo delivery of anticancer drugs after implantation at 
the tumour site. Similarly, another targeted PA to αvβ3 integrins [103] was 
developed but in this case with a spherical morphology [95] for targeting of 
glioblastoma, melanoma, breast, prostate, ovarian and pancreatic tumours. 
Palmitoyl and octadecyl-(ADA)2-RGD micelles with a were loaded with a 
micromolar CMC (9.00±1.73 µM), nanoparticulate size (194.63±44.86 nm) and 
almost neutral zeta potential (0.27±1.96 mV) were loaded with paclitaxel and 
tested in A2058 melanoma cells. In vitro studies illustrated that the PA micelles 
were uptaken by αvβ3 expressed on A2058 melanoma cells via an energy 
temperature dependent mechanism and induced significant toxicity [95]. The 
IC50 of paclitaxel loaded in micelles decreased 50% in αvβ3 integrin 
overexpressing cells and showed a 4 fold increase in normal cells when 
compared to free paclitaxel [95]. PAs have been also been shown to be able to 
deliver apart from anticancer drugs also biomacromolecules such as genes [92, 
104]. The (AF)6H5K15 peptide self-assembles into cationic micelles (102±19 nm, 
zeta potential of 22.8±0.2 mV) with a low CMC value of  approximately 0.042 
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mg/mL able to be loaded with doxorubicin and p53 gene [92], that were 
internalized by HepG2 human liver carcinoma cell line (Doxorubicin loaded 
micelles IC50 of 1.8 mg/L) and were able to induce significant gene expression 
levels. Additionally, toward novel anticancer delivery systems, Standley et al. 
tested a cationic palmitoyl-A4G3(KLAKLAK)2 PA for breast cancer [94]. 
Incorporating the (KLAKLAK)2 into nanofibers stabilized the peptides α-helical 
conformation and enable its permeability across cells inducing a caspase-
independent and Bax/Bak-independent cell death in MDA-MB-23 and SKBR-3 
breast cancer cells by lysing plasma membranes [94].  
 
PAs have also been assessed for their potential in type 1 diabetes for enabling 
pancreatic islet transplantation [93]. The latter although a promising treatment 
for diabetic patients remains challenging due to the lack of available donors, 
inefficient engraftment of transplanted cells and limited durability of long-term 
islet function. Palmitoyl-A4G3LRK2LGKA nanofibers were recently described to 
enhance the survival of the islets upon transplantation through the delivery of 
angiogenic factors such as vascular endothelial growth factor (VEGF) and 
fibroblast growth factor (FGF-2) [93]. Nanofibers conjugation with growth factors 
resulted in a  2-fold increase of cell viability and glucose stimulation index of 
murine pancreatic islets [93]. 
 
Finally, there are a number of papers reporting PAs loaded with model dyes 
such as pyrene or calcein as models for hydrophilic and hydrophobic drugs [87-
89, 93]. Pyrene, whose emission characteristics are often used to characterise 
the CMC of PAs [105], is commonly used as a hydrophobic drug model [87-89]. 
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PAs assembled into nanospheres were also lately shown  to be able to be 
loaded with a range of hydrophobic (BODIPY630, doxorubicin and paclitaxel), 
hydrophilic (Alexa 488) drugs and genes [106].  
6.0 Conclusions  
PAs, a class of peptides composed of a hydrophobic tail coupled to a 
hydrophilic headgroup via a spacer stabilised usually but not necessarily by β-
sheets show great potential as passively or active targeted delivery systems for 
both hydrophobic or hydrophilic drugs and biomacromolecules. Similar to other 
nanomedicines, the therapeutic cargo can be encapsulated or conjugated  to 
the range of available functional groups via an amide, ester or disulphide bond. 
By achieving a balance between the hydrogen, electrostatic, hydrophobic and 
π-π interactions, the supramolecular morphology and properties of the PAs 
including their pharmacokinetic properties can be tailored. Majority of the PAs 
undergoing preclinical testing involve the addition of a single palmitic acid tail 
and assemble supramolecularly as nanofibers. PAs have shown promise in 
permeation across challenging biological barriers such as the blood-brain 
barrier, tissue engineering and in intercellular and targeted delivery for drugs 
and genes. Due to their size and high axial morphology and propensity to elicit 
hydrogels, subcutaneously delivery remains the first choice. However, if the 
morphology and pharmacokinetic characteristics are tailored, non-parenteral 
(intravenous, oral or nasal) delivery routes are a possibility.  
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